A Case of Daratumumab-Induced Significant Decrease in Donor-Specific HLA Antibodies and Remission Induction Before Haploidentical Stem Cell Transplantation in a Refractory B-ALL Patient
Objective: To explore the method of eliminating donor-specific anti-HLA antibodies (DSA) in haploidentical stem cell transplantation (haplo-SCT). Methods: We present a refractory B-cell acute lymphoblastic leukemia (ALL) patient who had strongly positive DSA, but had no human leukocyte antigen–match...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-10-01
|
| Series: | Cell Transplantation |
| Online Access: | https://doi.org/10.1177/09636897221132502 |
| _version_ | 1828326742975053824 |
|---|---|
| author | Xin Li Haibo Zhu Tao Sui Xingli Zhao Qi Deng |
| author_facet | Xin Li Haibo Zhu Tao Sui Xingli Zhao Qi Deng |
| author_sort | Xin Li |
| collection | DOAJ |
| description | Objective: To explore the method of eliminating donor-specific anti-HLA antibodies (DSA) in haploidentical stem cell transplantation (haplo-SCT). Methods: We present a refractory B-cell acute lymphoblastic leukemia (ALL) patient who had strongly positive DSA, but had no human leukocyte antigen–matched donor. Although CD38 expression on leukemia cells was negative, daratumumab combined with etoposide and venetoclax therapy was chosen for her. Results: She achieved a significant decrease in DSA levels and complete remission on the combination therapy with daratumumab. She then received a haplo-SCT from a daughter as a donor and had a successful engraftment of donor stem cell. In haplo-SCT, strongly positive DSA levels, directed against donor HLA antigens, could be significantly reduced by daratumumab therapy before transplantation and successfully bridge subsequent haplo-SCT. Conclusion: Although CD38 expression is negative in leukemia cells, refractory B-ALL patients may still benefit from combination therapy with daratumumab. We need further clinical observation. |
| first_indexed | 2024-04-13T19:44:40Z |
| format | Article |
| id | doaj.art-a0b4437a627e45faa8532814741e4062 |
| institution | Directory Open Access Journal |
| issn | 1555-3892 |
| language | English |
| last_indexed | 2024-04-13T19:44:40Z |
| publishDate | 2022-10-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cell Transplantation |
| spelling | doaj.art-a0b4437a627e45faa8532814741e40622022-12-22T02:32:46ZengSAGE PublishingCell Transplantation1555-38922022-10-013110.1177/09636897221132502A Case of Daratumumab-Induced Significant Decrease in Donor-Specific HLA Antibodies and Remission Induction Before Haploidentical Stem Cell Transplantation in a Refractory B-ALL PatientXin Li0Haibo Zhu1Tao Sui2Xingli Zhao3Qi Deng4Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, ChinaDepartment of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, ChinaDepartment of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, ChinaDepartments of Oncology and Hematology, Tianjin People’s Hospital, School of Medicine, Nankai University, Tianjin, ChinaDepartment of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, ChinaObjective: To explore the method of eliminating donor-specific anti-HLA antibodies (DSA) in haploidentical stem cell transplantation (haplo-SCT). Methods: We present a refractory B-cell acute lymphoblastic leukemia (ALL) patient who had strongly positive DSA, but had no human leukocyte antigen–matched donor. Although CD38 expression on leukemia cells was negative, daratumumab combined with etoposide and venetoclax therapy was chosen for her. Results: She achieved a significant decrease in DSA levels and complete remission on the combination therapy with daratumumab. She then received a haplo-SCT from a daughter as a donor and had a successful engraftment of donor stem cell. In haplo-SCT, strongly positive DSA levels, directed against donor HLA antigens, could be significantly reduced by daratumumab therapy before transplantation and successfully bridge subsequent haplo-SCT. Conclusion: Although CD38 expression is negative in leukemia cells, refractory B-ALL patients may still benefit from combination therapy with daratumumab. We need further clinical observation.https://doi.org/10.1177/09636897221132502 |
| spellingShingle | Xin Li Haibo Zhu Tao Sui Xingli Zhao Qi Deng A Case of Daratumumab-Induced Significant Decrease in Donor-Specific HLA Antibodies and Remission Induction Before Haploidentical Stem Cell Transplantation in a Refractory B-ALL Patient Cell Transplantation |
| title | A Case of Daratumumab-Induced Significant Decrease in Donor-Specific HLA Antibodies and Remission Induction Before Haploidentical Stem Cell Transplantation in a Refractory B-ALL Patient |
| title_full | A Case of Daratumumab-Induced Significant Decrease in Donor-Specific HLA Antibodies and Remission Induction Before Haploidentical Stem Cell Transplantation in a Refractory B-ALL Patient |
| title_fullStr | A Case of Daratumumab-Induced Significant Decrease in Donor-Specific HLA Antibodies and Remission Induction Before Haploidentical Stem Cell Transplantation in a Refractory B-ALL Patient |
| title_full_unstemmed | A Case of Daratumumab-Induced Significant Decrease in Donor-Specific HLA Antibodies and Remission Induction Before Haploidentical Stem Cell Transplantation in a Refractory B-ALL Patient |
| title_short | A Case of Daratumumab-Induced Significant Decrease in Donor-Specific HLA Antibodies and Remission Induction Before Haploidentical Stem Cell Transplantation in a Refractory B-ALL Patient |
| title_sort | case of daratumumab induced significant decrease in donor specific hla antibodies and remission induction before haploidentical stem cell transplantation in a refractory b all patient |
| url | https://doi.org/10.1177/09636897221132502 |
| work_keys_str_mv | AT xinli acaseofdaratumumabinducedsignificantdecreaseindonorspecifichlaantibodiesandremissioninductionbeforehaploidenticalstemcelltransplantationinarefractoryballpatient AT haibozhu acaseofdaratumumabinducedsignificantdecreaseindonorspecifichlaantibodiesandremissioninductionbeforehaploidenticalstemcelltransplantationinarefractoryballpatient AT taosui acaseofdaratumumabinducedsignificantdecreaseindonorspecifichlaantibodiesandremissioninductionbeforehaploidenticalstemcelltransplantationinarefractoryballpatient AT xinglizhao acaseofdaratumumabinducedsignificantdecreaseindonorspecifichlaantibodiesandremissioninductionbeforehaploidenticalstemcelltransplantationinarefractoryballpatient AT qideng acaseofdaratumumabinducedsignificantdecreaseindonorspecifichlaantibodiesandremissioninductionbeforehaploidenticalstemcelltransplantationinarefractoryballpatient AT xinli caseofdaratumumabinducedsignificantdecreaseindonorspecifichlaantibodiesandremissioninductionbeforehaploidenticalstemcelltransplantationinarefractoryballpatient AT haibozhu caseofdaratumumabinducedsignificantdecreaseindonorspecifichlaantibodiesandremissioninductionbeforehaploidenticalstemcelltransplantationinarefractoryballpatient AT taosui caseofdaratumumabinducedsignificantdecreaseindonorspecifichlaantibodiesandremissioninductionbeforehaploidenticalstemcelltransplantationinarefractoryballpatient AT xinglizhao caseofdaratumumabinducedsignificantdecreaseindonorspecifichlaantibodiesandremissioninductionbeforehaploidenticalstemcelltransplantationinarefractoryballpatient AT qideng caseofdaratumumabinducedsignificantdecreaseindonorspecifichlaantibodiesandremissioninductionbeforehaploidenticalstemcelltransplantationinarefractoryballpatient |